Want to see DE:BAYN full AI Analyst Report?
Top Page
Bayer
(XETRA:BAYN)
Select Model
Select Model
Rating:57Neutral
Price Target:
€52.00
▲(12.90% Upside)
Action:Reiterated
Date:08/10/26
The score is held back primarily by weak financial performance (multi-year net losses, inconsistent operating profitability, and historically elevated leverage), partially offset by continued positive—though volatile—free cash flow. Technicals are a key support with a clear uptrend and positive momentum indicators. Valuation is mixed: a high dividend yield helps, but the negative P/E underscores that current earnings are under pressure.
Positive Factors
Diversified Business Model
Bayer's dual focus in Pharmaceuticals and Crop Science provides durable revenue diversification across healthcare and agriculture. This reduces exposure to single-market cycles, leverages separate distribution channels and regulatory moats, and supports long-term cash generation and R&D reinvestment.
Negative Factors
Elevated Leverage
Multi-year leverage above equity limits financial flexibility and raises interest and refinancing risk. Elevated debt constrains strategic options such as large M&A or accelerated buybacks, increases sensitivity to macro shocks, and can pressure credit metrics and investment capacity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Business Model
Bayer's dual focus in Pharmaceuticals and Crop Science provides durable revenue diversification across healthcare and agriculture. This reduces exposure to single-market cycles, leverages separate distribution channels and regulatory moats, and supports long-term cash generation and R&D reinvestment.
Read all positive factors
Bayer (BAYN) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€46.95B
Dividend Yield0.23%
Average Volume (3M)2.24M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth-1.73%
EPS Growth49.15%
CountryDE
Employees87,830
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-1.76
Shares Outstanding982,424,100
10 Day Avg. Volume2,239,372
30 Day Avg. Volume2,240,598
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.40
Price to Sales (P/S)0.80
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€56.64Price Target Upside22.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.48
Revenue Forecast (FY)€45.74B
Bayer Business Overview & Revenue Model
Company Description
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consum...
How the Company Makes Money
Bayer makes money mainly by selling products and related services across its two operating divisions.
1) Pharmaceuticals revenue model:
- Prescription drug sales: The core revenue stream is the sale of patented and off-patent prescription medicin...
Bayer Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
48
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.38B | 45.58B | 46.61B | 47.64B | 50.74B | 44.08B |
| Gross Profit | 26.80B | 26.98B | 25.34B | 27.89B | 30.87B | 27.27B |
| EBITDA | 5.08B | 2.65B | 3.67B | 4.05B | 10.29B | 7.02B |
| Net Income | -1.74B | -3.62B | -2.55B | -2.94B | 4.15B | 1.00B |
Balance Sheet | ||||||
| Total Assets | 107.28B | 110.61B | 110.85B | 116.26B | 124.88B | 120.24B |
| Cash, Cash Equivalents and Short-Term Investments | 5.08B | 7.86B | 8.09B | 10.59B | 10.15B | 7.74B |
| Total Debt | 38.43B | 37.44B | 40.74B | 44.79B | 41.65B | 39.53B |
| Total Liabilities | 77.58B | 84.54B | 78.81B | 83.18B | 85.95B | 87.07B |
| Stockholders Equity | 29.58B | 25.95B | 31.91B | 32.93B | 38.77B | 33.02B |
Cash Flow | ||||||
| Free Cash Flow | 1.45B | 2.08B | 4.59B | 2.37B | 4.14B | 2.48B |
| Operating Cash Flow | 4.16B | 4.57B | 7.37B | 5.12B | 7.09B | 5.09B |
| Investing Cash Flow | -2.18B | -1.61B | 164.00M | -4.01B | -2.38B | 855.00M |
| Financing Cash Flow | -2.31B | -2.19B | -7.18B | -679.00M | -4.22B | -5.64B |
Bayer Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | €16.97B | 18.31 | 10.66% | 1.28% | -2.50% | 8.61% | |
74 Outperform | €2.89B | 19.33 | 4.27% | 1.98% | -0.06% | -38.81% | |
70 Neutral | €45.65B | 7.68 | 17.00% | 5.16% | -8.88% | 1431.12% | |
60 Neutral | €1.45B | 43.42 | 4.19% | 1.82% | ― | ― | |
57 Neutral | €46.95B | -27.15 | -7.52% | 0.24% | -1.73% | 49.15% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
DE:BAYN
Bayer
47.79
20.20
73.21%
DE:BAS
BASF SE
51.15
6.71
15.09%
DE:BEI
Beiersdorf
78.32
-22.99
-22.70%
DE:AFX
Carl Zeiss Meditec
32.28
-10.57
-24.68%
DE:COP
CompuGroup Medical
27.50
4.43
19.23%
Bayer Corporate Events
Regulatory Filings and Compliance
Ubben-Linked Trust Buys €1.19 Million in Bayer Shares
Positive
Jul 1, 2026
Bayer disclosed a managers’ transaction in which the Jeffrey and Laura Ubben 2000 Trust, a person closely associated with supervisory board member Jeffrey Ubben, purchased Bayer shares on the Xetra trading platform. The trust executed numero...
Business Operations and StrategyRegulatory Filings and Compliance
Bayer Board Member Hartmann Buys Shares Under Management Commitment Program
Positive
Jun 9, 2026
Bayer disclosed a managers’ transaction involving Board of Management member Dr. Judith Hartmann, who purchased Bayer shares on June 5, 2026 via the Xetra trading platform. The purchases, made at a price of €35.84 per share and totalin...
Regulatory Filings and Compliance
Insider-Linked Investor Buys €1.69 Million in Bayer Shares
Positive
Jun 3, 2026
Bayer disclosed a managers’ transaction under EU Market Abuse Regulation, reporting that SF Investment One Pte Ltd., a person closely associated with supervisory board member Marcel Smits, purchased Bayer shares. The transaction involved Bay...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.